bluebird bio (NASDAQ: BLUE) reported Q2 EPS of ($0.67), $0.03 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $6.9 million versus the consensus estimate of $11.11 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.